|Mr. Mauro Severino Ajani||Founder & Exec. Chairman||395.44k||N/A||1955|
|Mr. Alessandro E. Della Cha LL.M||CEO & Exec. Director||599.23k||N/A||1963|
|Mr. Ngo Dinh Nhan||Head of R&D - AI & Biomedical IT||N/A||N/A||1979|
|Mr. Giulio Evangelisti||Head of Production, AI & Biomedical IT||N/A||N/A||1970|
|Mr. Niall Donnelly||Chief Financial Officer||N/A||N/A||1972|
|Mr. Marco Lecchi||Chief Operating Officer||N/A||N/A||1964|
|Mr. Davide Malavasi||Qualified Person & Technical Director||N/A||N/A||1973|
|Mr. Luigi Longo||Chief Scientific Officer||N/A||N/A||1979|
|Ms. Hazel Winchester||Head of Investor Relations||N/A||N/A||1971|
|Mr. Biagio Vigano||Chief People Officer||N/A||N/A||1974|
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Cosmo Pharmaceuticals N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.